# Loxo Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/loxo-oncology

- Industry: Pharmaceuticals
- Headquarters: Delaware, US
- Website: www.loxooncology.com
- Total disclosed funding: $67M
- Latest round: Series B (May 6, 2014)
- Investors on record: 3

## About

Loxo Oncology, Inc. is focused on developing targeted therapies for patients with genetically defined cancers, utilizing innovative drug discovery techniques to improve treatment specificity and efficacy.Loxo Oncology, Inc., founded in 2013 and headquartered in Delaware, US, specializes in developing targeted therapies for oncology. The company has not undergone any major strategic pivots and does not have any noted subsidiaries. It was created by a team of experienced industry professionals. In August 2014, Loxo raised USD 68.9 mn through an IPO, marking a significant funding milestone. To date, the company has completed four funding deals, raising a total of USD 8000.00 mn.Loxo Oncology develops innovative cancer therapies tailored to specific genetic mutations, aiming to provide more effective treatment options for patients. Their portfolio includes drug candidates that target unique genetic drivers of cancer, improving patient outcomes. The company's products are primarily aimed at oncology healthcare providers, hospitals, and specialized clinics, extending access to patients with rare and challenging cancers.In the most recent fiscal year of 2017, Loxo Oncology reported a revenue of USD 21.30 mn, while experiencing an EBITDA loss of USD 152.19 mn. Their revenue is generated through the clinical development of their product pipeline and potential future commercial sales.Loxo Oncology plans to further develop several new cancer therapies aimed at specific genetic targets, with anticipated launches in the coming years. The company is looking to expand its market reach into Europe and Asia by 2025, aiming to provide targeted treatments to a larger patient population. Recent funding from the IPO will support these growth initiatives, which include the advancement of clinical trials and expanding their geographic footprint.

## Funding rounds

- Series B, May 6, 2014, $24M — New Enterprise Associates, OrbiMed Advisors, Aisling Capital
- Series A, Oct 3, 2013, $33M — OrbiMed Advisors, Aisling Capital
- Series A, Jul 11, 2013, $10M — Aisling Capital

## Investors

- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B